Effectiveness and safety of intraoperative radiotherapy (IORT) with low-energy X-rays (INTRABEAM®) for accelerated partial breast irradiation (APBI)
-
Maria Laplana [1] ; Marta García-Marqueta [1] ; Juan José Sánchez-Fernández [2] ; Evelyn Martínez-Pérez [1] ; Héctor Pérez-Montero [1] ; Irene Martínez-Montesinos [1] ; Arantxa Eraso [1] ; Pablo Saldaña [1] ; Roberto Martín [1] ; Marta Irene Martín [1] ; Maria Jesús Pla [2] ; Amparo García-Tejedor [2] ; Ferran Guedea [1]
-
[1] Institute Catalá Oncología
Institute Catalá Oncología
Barcelona, España
-
[2] Universitat de Barcelona
Universitat de Barcelona
Barcelona, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 9, 2022, págs. 1732-1743
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose To evaluate treatment outcomes in patients with early-stage breast cancer (ESBC) treated with targeted intraoperative radiation therapy (IORT) administered as accelerated partial breast irradiation (APBI).
Methods Between December 2014 and May 2019, 50 patients diagnosed with ESBC were treated with a 50 kilovoltage (kV) X-ray source with a single dose of 20 Gy using the Intrabeam® radiotherapy delivery system. All patients were followed prospectively to assess local control (LC), disease-free survival (DFS), cancer-specific survival (CSS), overall survival (OS), radiation-induced toxicity, and cosmetic outcomes. We also evaluated the prognostic implications of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).
Results Median follow-up was 53 months. Mean patient age was 70 years. The mean duration of radiation delivery was 22.25 min. Two patients developed a recurrence. One death was recorded. Elevated pretreatment NLR levels were a significant risk factor for mortality (p = 0.0026). The most common treatment-related toxicities were breast induration (30%) and seroma (18%). Five-year LC, DFS, CSS, and OS rates were 97.1%, 93.9%, 100%, and 94.4%, respectively. Cosmesis was excellent or good in most cases (94%).
Conclusion These findings confirm the effectiveness of a single dose of 20 Gy of IORT with the Intrabeam device as APBI. The toxicity profile was good with excellent cosmesis. These results provide further support for the clinical use of APBI in well-selected patients.
